NEW YORK (GenomeWeb News) — Baylor College of Medicine’s Human Genome Sequencing Center plans to buy seven additional 454 Life Sciences FLX genome sequencers from Roche by the end of the year as it follows a long-term strategy to take on large-scale resequencing projects, Baylor said today.
The installments, which will increase to 10 Baylor’s installed base of FLXs, will enable the center to take on resequencing projects using a new capture technology developed through a collaboration with Roche business NimbleGen Systems.
Baylor and Roche have also expanded a previous collaboration in which the sequencing center gains early access to updates to the FLX system, which “will include an increase in sequence read length beyond 400 base pairs,” Baylor said.
NimbleGen’s capture technology allows users to amplify large numbers of DNA targets for next-generation sequencing, Baylor told GenomeWeb Daily News sister publication In Sequence this week.
Preliminary work from the NimbleGen collaboration, which appears in this week’s Nature Methods, uses microarrays to capture up to 6,500 human exons for sequence analysis, “reducing the dependence on large-scale" PCR, BCM said in a statement.
The new instruments will also be applied to the analysis of bacterial genomes in a National Institutes of Health-supported effort to analyze metagenomes of benign and pathogenic bacteria that live in human hosts.
Financial terms of the agreement were not released.
In addition to the three existing FLX systems, Baylor owns one Illumina Genome Analyzer and a SOLiD sequencer from Applied Biosystems.
A comprehensive version of this article appears in the current issue of In Sequence, a GenomeWeb Daily News sister publication.